Background: Treatment-resistant melanoma remains a significant clinical challenge despite advances in immunotherapy. Combination approaches targeting multiple immune checkpoints have shown promise in preclinical studies but require rigorous clinical evaluation.
Methods: We conducted a multicenter, randomized, double-blind Phase II trial enrolling 312 patients with advanced melanoma who had progressed on prior anti-PD-1 therapy. Patients were randomized 1:1:1 to receive: (A) nivolumab plus ipilimumab, (B) nivolumab plus relatlimab, or (C) nivolumab plus experimental agent XYZ-4821. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.
Results: At median follow-up of 18.3 months, median PFS was 4.2 months (arm A), 5.8 months (arm B), and 8.1 months (arm C). The combination of nivolumab plus XYZ-4821 demonstrated superior PFS compared to nivolumab plus ipilimumab (HR 0.62, 95% CI 0.44-0.87, p=0.006). Grade 3-4 treatment-related adverse events occurred in 42%, 28%, and 31% of patients in arms A, B, and C, respectively.
Conclusions: The novel combination of nivolumab plus XYZ-4821 showed improved efficacy with a manageable safety profile in treatment-resistant melanoma, warranting further investigation in Phase III trials.
Melanoma
Immunotherapy
Checkpoint inhibitors
Combination therapy
Treatment resistance
Clinical trial
1. The statistical analysis section needs clarification regarding the handling of patients who discontinued treatment early.
2. Figure 2 would benefit from including confidence intervals for the Kaplan-Meier curves.
3. The discussion should address the potential mechanisms underlying the observed differences in toxicity profiles between arms.